{"title":"自身免疫性结缔组织疾病中非瘢痕性脱发的发生率","authors":"Yahya Argobi","doi":"10.36849/JDD.7750","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Autoimmune connective tissue diseases (ACTDs) are relatively rare systemic diseases featured by immune dysregulation and often have prominent cutaneous manifestations. The most common is systemic lupus erythematosus (SLE), dermatomyositis (DM), systemic sclerosis (SSc), Sjogren syndrome (SJO), undifferentiated connective tissue disease (UCTD), and mixed connective tissue disease (MCTD). Alopecia is one of the most common symptoms of these diseases, with significant impact on the quality of life of these patients.</p><p><strong>Objective: </strong>Our aim is to better characterize non-scarring alopecia in ACTDs.</p><p><strong>Methods: </strong>A retrospective chart review study of patients seen at the Autoimmune Connective Tissue Diseases clinic at Massachusetts General Hospital, Boston, MA, was conducted from November 2012 to January 2018. The study was reviewed and approved by Partners IRB.</p><p><strong>Results: </strong>A total number of 1486 visits where 734 were new patients, and 241 patients with ACTDs included in our analysis. Of the new patients, 80% were female and 20% were male, with an average age of 51 years. Of patients with MCTD, 46.6% presented with non-scarring alopecia at their initial evaluation. Of patients with SLE, 36% presented with non-scarring alopecia. Of the 32 patients with SJO, 28% reported diffuse non-scarring alopecia. Of patients with UCTD, 22% presented with diffuse non-scarring alopecia. Only 9.5% of our patients with DM and 9% of our patients with SSc presented with diffuse non-scarring alopecia.</p><p><strong>Conclusion: </strong>Alopecia is common in all ACTDs and often under evaluated. Treatment of alopecia in ACTDs can be challenging, and oftentimes patients require joint management and work-up. J Drugs Dermatol. 2025;24(3):246-249. doi:10.36849/JDD.7750.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 3","pages":"246-249"},"PeriodicalIF":1.5000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Frequency of Non-Scarring Alopecia in Autoimmune Connective Tissue Diseases.\",\"authors\":\"Yahya Argobi\",\"doi\":\"10.36849/JDD.7750\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Autoimmune connective tissue diseases (ACTDs) are relatively rare systemic diseases featured by immune dysregulation and often have prominent cutaneous manifestations. The most common is systemic lupus erythematosus (SLE), dermatomyositis (DM), systemic sclerosis (SSc), Sjogren syndrome (SJO), undifferentiated connective tissue disease (UCTD), and mixed connective tissue disease (MCTD). Alopecia is one of the most common symptoms of these diseases, with significant impact on the quality of life of these patients.</p><p><strong>Objective: </strong>Our aim is to better characterize non-scarring alopecia in ACTDs.</p><p><strong>Methods: </strong>A retrospective chart review study of patients seen at the Autoimmune Connective Tissue Diseases clinic at Massachusetts General Hospital, Boston, MA, was conducted from November 2012 to January 2018. The study was reviewed and approved by Partners IRB.</p><p><strong>Results: </strong>A total number of 1486 visits where 734 were new patients, and 241 patients with ACTDs included in our analysis. Of the new patients, 80% were female and 20% were male, with an average age of 51 years. Of patients with MCTD, 46.6% presented with non-scarring alopecia at their initial evaluation. Of patients with SLE, 36% presented with non-scarring alopecia. Of the 32 patients with SJO, 28% reported diffuse non-scarring alopecia. Of patients with UCTD, 22% presented with diffuse non-scarring alopecia. Only 9.5% of our patients with DM and 9% of our patients with SSc presented with diffuse non-scarring alopecia.</p><p><strong>Conclusion: </strong>Alopecia is common in all ACTDs and often under evaluated. Treatment of alopecia in ACTDs can be challenging, and oftentimes patients require joint management and work-up. J Drugs Dermatol. 2025;24(3):246-249. doi:10.36849/JDD.7750.</p>\",\"PeriodicalId\":15566,\"journal\":{\"name\":\"Journal of Drugs in Dermatology\",\"volume\":\"24 3\",\"pages\":\"246-249\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2025-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Drugs in Dermatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.36849/JDD.7750\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Drugs in Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.36849/JDD.7750","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}
The Frequency of Non-Scarring Alopecia in Autoimmune Connective Tissue Diseases.
Background: Autoimmune connective tissue diseases (ACTDs) are relatively rare systemic diseases featured by immune dysregulation and often have prominent cutaneous manifestations. The most common is systemic lupus erythematosus (SLE), dermatomyositis (DM), systemic sclerosis (SSc), Sjogren syndrome (SJO), undifferentiated connective tissue disease (UCTD), and mixed connective tissue disease (MCTD). Alopecia is one of the most common symptoms of these diseases, with significant impact on the quality of life of these patients.
Objective: Our aim is to better characterize non-scarring alopecia in ACTDs.
Methods: A retrospective chart review study of patients seen at the Autoimmune Connective Tissue Diseases clinic at Massachusetts General Hospital, Boston, MA, was conducted from November 2012 to January 2018. The study was reviewed and approved by Partners IRB.
Results: A total number of 1486 visits where 734 were new patients, and 241 patients with ACTDs included in our analysis. Of the new patients, 80% were female and 20% were male, with an average age of 51 years. Of patients with MCTD, 46.6% presented with non-scarring alopecia at their initial evaluation. Of patients with SLE, 36% presented with non-scarring alopecia. Of the 32 patients with SJO, 28% reported diffuse non-scarring alopecia. Of patients with UCTD, 22% presented with diffuse non-scarring alopecia. Only 9.5% of our patients with DM and 9% of our patients with SSc presented with diffuse non-scarring alopecia.
Conclusion: Alopecia is common in all ACTDs and often under evaluated. Treatment of alopecia in ACTDs can be challenging, and oftentimes patients require joint management and work-up. J Drugs Dermatol. 2025;24(3):246-249. doi:10.36849/JDD.7750.
期刊介绍:
The Journal of Drugs in Dermatology (JDD) is a peer-reviewed publication indexed with MEDLINE®/PubMed® that was founded by the renowned Dr. Perry Robins MD. Founded in 2002, it offers one of the fastest routes to disseminate dermatologic information and is considered the fastest growing publication in dermatology.
We present original articles, award-winning case reports, and timely features pertaining to new methods, techniques, drug therapy, and devices in dermatology that provide readers with peer reviewed content of the utmost quality.
Our high standards of content are maintained through a balanced, peer-review process. Articles are reviewed by an International Editorial Board of over 160 renowned experts.